A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

NCT06323161 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo

Sponsor

Novo Nordisk A/S